公开(公告)号：AU2856900A

公开(公告)日：2000-08-18

申请号：AU2856900

申请日：2000-01-25

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  CRISTINA DANIELA BARLOCCO ,  DAANEN JEROME F ,  DART MICHAEL J ,  MEYER MICHAEL D ,  RYTHER KEITH B ,  SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  TOUPENCE RICHARD B

IPC: A61K31/00 ,  A61K31/407 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/502 ,  A61P9/10 ,  A61P15/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D401/08 ,  C07D471/08 ,  C07D487/08 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  A61K31/395

Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.

公开(公告)号：AU709784B2

公开(公告)日：1999-09-09

申请号：AU5804596

申请日：1996-05-28

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  LIN NAN-HORNG ,  RYTHER KEITH B ,  HE YUN

IPC: A61K31/00 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P25/00 ,  A61P25/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds having formula (I), wherein * is a chiral center and n, X, R , R , A andB are specifically defined, which are useful in controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions therof; and use of said compositions to selectively control synaptic transmission in mammals.

公开(公告)号：CA2285263A1

公开(公告)日：1998-10-22

申请号：CA2285263

申请日：1998-04-10

Applicant: ABBOTT LAB

Inventor： RYTHER KEITH B ,  HOLLADAY MARK W ,  WASICAK JAMES T ,  LI YIHONG ,  LIN NAN-HORNG ,  DAANEN JEROME F ,  ELLIOTT RICHARD L ,  DART MICHAEL J ,  HE YUN

IPC: A61K31/4355 ,  A61K31/4365 ,  A61P25/00 ,  A61P43/00 ,  C07D491/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  A61K31/435

Abstract: Novel heterocyclic ether compounds having formula (I) wherein A, m, R, X, Y1, Y2 and Y3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.

公开(公告)号：ZA981301B

公开(公告)日：1998-08-28

申请号：ZA981301

申请日：1998-02-17

Applicant: ABBOTT LAB

Inventor： WASICAK JAMES T ,  GARVEY DAVID S ,  HOLLADAY MARK W ,  LIN NAN-HORNG ,  RYTHER KEITH B

IPC: A61P25/04 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/4725 ,  A61P25/00 ,  A61P43/00 ,  C07D487/04 ,  C07D ,  A61K

Abstract: 7a-Substituted hexahydro-1H-pyrrolizine compounds having the formula wherein A is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to selectively control synaptic transmission in mammals.

公开(公告)号：CA2698384A1

公开(公告)日：1998-06-18

申请号：CA2698384

申请日：1997-12-10

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  ARNERIC STEPHEN P ,  BAI HAO ,  DART MICHAEL J ,  LIN NAN-HORNG ,  LYNCH JOHN K ,  OR YAT SUN ,  RYTHER KEITH B ,  SULLIVAN JAMES P ,  WASICAK JAMES T ,  EHRLICH PAUL P

IPC: A61P25/04 ,  C07D205/04 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/485 ,  A61P25/28 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

公开(公告)号：CA2698384C

公开(公告)日：2012-05-01

申请号：CA2698384

申请日：1997-12-10

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  ARNERIC STEPHEN P ,  BAI HAO ,  DART MICHAEL J ,  LIN NAN-HORNG ,  LYNCH JOHN K ,  OR YAT SUN ,  RYTHER KEITH B ,  SULLIVAN JAMES P ,  WASICAK JAMES T ,  EHRLICH PAUL P

IPC: A61P25/04 ,  C07D205/04 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/485 ,  A61P25/28 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14

Abstract: The invention relates to an azetidine compound of formula (see formula II) or (see formula III) involved in the preparation of selected compounds of formula (1) (see formula I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：CA2361525C

公开(公告)日：2009-12-08

申请号：CA2361525

申请日：2000-01-25

Applicant: ABBOTT LAB

Inventor： DAANEN JEROME F ,  SCHRIMPF MICHAEL R ,  RYTHER KEITH B ,  MEYER MICHAEL D ,  BUNNELLE WILLIAM H ,  DART MICHAEL J ,  SIPPY KEVIN B ,  CRISTINA DANIELA BARLOCCO ,  TOUPENCE RICHARD B

IPC: C07D487/08 ,  A61K31/00 ,  A61K31/395 ,  A61K31/407 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/502 ,  A61P9/10 ,  A61P15/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D209/00 ,  C07D221/00 ,  C07D241/00 ,  C07D243/00 ,  C07D401/08 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH 2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covale nt bond, CH2, and CH2CH2; Z is selected from the group consisting of CH2, CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h) , (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.

公开(公告)号：CA2706586A1

公开(公告)日：2009-05-28

申请号：CA2706586

申请日：2008-11-20

Applicant: ABBOTT LAB

Inventor： FLORJANCIC ALAN S ,  DART MICHAEL J ,  RYTHER KEITH B ,  PEREZ-MEDRANO ARTURO ,  CARROLL WILLIAM A ,  PATEL MEENA V ,  TIETJE KARIN ROSEMARIE ,  LI TONGMEI ,  KOLASA TEODOZYJ ,  GALLAGHER MEGAN E ,  PEDDI SRIDHAR ,  FROST JENNIFER M ,  NELSON DEREK W

IPC: C07D277/46 ,  A61K31/425 ,  A61P25/04 ,  A61P29/00 ,  C07D277/48 ,  C07D277/60 ,  C07D417/06 ,  C07D495/04 ,  C07D513/04

Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

公开(公告)号：CR10473A

公开(公告)日：2009-01-12

申请号：CR10473

申请日：2008-11-28

Applicant: ABBOTT LAB

Inventor： DART MICHAEL J ,  CARROL WILLIAM A ,  FLORJANCIC ALAN S ,  FROST JENNIFER M ,  GALLAGHER MEGAN E ,  LI TONGMEI ,  NELSON DEREK W ,  PATEL MEENA V ,  PEDDI SRIDHAR ,  PEREZ-MEDRANO ARTURO ,  RYTHER KEITH B ,  TIETJE KARIN ROSEMARIE ,  KOLASA TEODOZYJ

IPC: A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/429 ,  A61P29/00 ,  C07D277/46 ,  C07D277/48 ,  C07D277/60 ,  C07D277/82 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D513/04

Abstract: Compuestos de la formula (I), o sales farmaceuticas, prodrogas, sales de prodrogas, o combinaciones de los mismos, donde R1, R2, R3, R4 y L1 se definen en la memoria descriptiva, composiciones que comprenden dichos compuestos, y metodos para tratar condiciones y trastornos usando dichos compuestos y composiciones. La presente invencion tambien se refiere a compuestos de formula (II) o sales farmaceuticas, prodrogas, sales de prodrogas, o combinaciones de los mismos, donde R1a, R2a y Rxn tienen los valores definidos en la memoria descriptiva, composiciones que comprenden dichos compuestos, y metodos para tratar condiciones y trastornos usando dichos compuestos y composiciones.

公开(公告)号：NO20085385L

公开(公告)日：2008-12-29

申请号：NO20085385

申请日：2008-12-29

Applicant: ABBOTT LAB

Inventor： RYTHER KEITH B ,  KOLASA TEODOZYJ ,  PATEL MEENA V ,  DART MICHAEL J ,  CARROLL WILLIAM A ,  FLORJANCIC ALAN S ,  FROST JENNIFER M ,  GALLAGHER MEGAN E ,  LI TONGMEI ,  NELSON DEREK W ,  PEDDI SRIDHAR ,  PEREZ-MEDRANO ARTURO ,  TIETJE KARIN ROSEMARIE

IPC: C07D277/28

Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L1 are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.